Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Agios Pharmaceuticals (NQ: AGIO)
53.80 USD  +0.94 (+1.78%)
Streaming Delayed Price  /  Updated: 4:11 PM EST, Jan 21, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 916,770
Open 52.67
Bid (Size) 51.84 (2)
Ask (Size) 54.49 (2)
Prev. Close 52.86
Today's Range 51.98 - 54.44
52wk Range 28.36 - 68.94
Shares Outstanding 57,605,621
Dividend Yield N/A
Performance
YTD
+13.22%
+13.22%
1 Month
+8.31%
+8.31%
3 Month
+60.98%
+60.98%
6 Month
+14.01%
+14.01%
1 Year
+2.93%
+2.93%
Top News
More News
Agios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones
from GlobeNewswire News Releases
Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020
from GlobeNewswire News Releases
More News
Read More
TIO Bioventures Expands and Strengthens Team with the Appointment of Industry Veteran Rachel W. Humphrey, M.D., as Head of R&D at TIO Discovery
from Business Wire News Releases
TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets
from Business Wire News Releases
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation
from GlobeNewswire News Releases
Why Pharmaceutical R&D Global Spending Could Exceed $200 Billion by 2024
from PR Newswire
Why Pharmaceutical R&D Global Spending Could Exceed $200 Billion By 2024
category Featured News
from FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
from GlobeNewswire News Releases
Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)
from GlobeNewswire News Releases
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
from GlobeNewswire News Releases
Uptrend Call Working As Agios Pharmaceut Stock Rises 47.2% (AGIO)
from Comtex SmarTrend® News Briefs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.